Journal of Clinical Review & Case Reports(JCRC)

Senior Manager, Process Development, Canada

Publications

• Research Article   
  Tucaresol: A Clinical Stage Oral Candidate Drug with Two Distinct Antiviral Mechanisms
  Author(s): Christopher L. Penney*, Boulos Zacharie and Jean-Simon Duceppe
  
  Globally, approximately 39 million people are living with Human Immunodeficiency Virus, HIV, arising from approximately 86 million infections since this epidemic began in 1981. However, the number of HIV infections is unevenly distributed with two thirds of global infections confined to Sub-Saharan Africa. Due to viral drug resistance, the most effective treatment requires a triple drug combination thereby adding to the complexity and cost of therapy. As such, many people living with HIV or at risk of infection do not have access to prevention or treatment of this potentially fatal disease. There is no cure for HIV [1]. Tucaresol is an orally active clinical stage drug which functions as a host targeted antiviral agent by protection or reconstitution of CD4+ T helper immune cells. We report herein that Tucaresol also displays in-vitro activity against HIV in infected human peripheral .. Read More»
  

  Abstract HTML PDF